NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Vivosim Labs, Inc. VIVS
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$131,000
▼ 9.0% vs FY2024
EPS · FY25
$-5.35
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-294.8%
Net margin · FY25
-10567.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 131,000.00
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 10567 cents on every revenue dollar this year.
Per share
USD -5.35
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-294.8%
Return on equity, FY2025
ROE
Operating margin-8768.7%
Net margin-10567.2%
Return on assets-125.6%
Each USD of equity lost 295 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−29.3%
−21.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years+58.8%
Change, 10 years—
The share count grew 59% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.4M
total assets, end of FY2025
Total assetsUSD 7.4M
EquityUSD -1.1M
CashUSD 5.0M
Current ratio2.38×
Equity funds -15% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−5.35
−1.70
−19.25
−1.98
−1.32
−2.44
−2.80
−0.23
−0.32
−0.39
−0.43
−0.38
−0.35
−1.01
−0.19
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−294.8
−35.3
−155.0
−75.8
−33.0
−51.1
−59.5
−65.9
−65.1
−61.7
−69.6
−62.0
−120.3
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.01
0.01
0.01
0.01
0.12
0.11
0.10
0.09
0.08
0.08
0.06
0.02
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
44 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed